Outcomes of treatment with pyrimine 60 in Thai myasthenia gravis patients

Abstract

Myasthenia gravis is a neurological disease that causes poor quality of life. Mestinon® is the drug of choice. However, using the original medication may lead to high costs particularly in developing countries. We did a pilot study in previously diagnosed, stable generalized myasthenia gravis patients by switching Mestinon® to pyrimine 60, a generic form. After we enrolled 13 patients, 6 patients responded, 4 patients did not respond, and 4 patients had severe dry mouth and throat from pyrimine 60. Clinical characters, SF-36 scores, and composite scores in those who responded, did not response, and had side effects were compared. No patients had serious side effects or myasthenic crisis. In conclusion, pyrimine 60 may be as effective as mestinon® with minor side effects.